High Marks for Novel Neoadjuvant Regimen (CME/CE)

(MedPage Today) -- T-DM1/pertuzumab tops standard therapy in HER2-positive breast cancer

Source: MedPage Today Hematology/Oncology - April 20, 2016 Category: Hematology Source Type: news